Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) has scheduled the release of its half-yearly results for the period ending June 30, 2025, to be announced on Thursday, August 28, 2025. The company will host a presentation and conference call for analysts and shareholders at 9:00 AM EDT / 2:00 PM BST on the same day. Interested parties can access the presentation webcast through PureTech's investor relations website.
Vedanta Biosciences, a PureTech (NASDAQ: PRTC) Founded Entity, announced that its Phase 2 COLLECTiVE202 study of VE202 for ulcerative colitis (UC) treatment failed to meet its primary endpoint of endoscopic response. While the treatment was well-tolerated with no serious adverse events, the response rates were not statistically different from placebo.
The company will now focus on its lead program VE303, currently in Phase 3 trials for recurrent Clostridioides difficile infection (CDI). VE303 previously showed promising Phase 2 results with a 30.5% absolute risk reduction compared to placebo. The program has received Fast Track and Orphan Drug designations from the FDA. Additionally, Vedanta is advancing VE707 for preventing multidrug-resistant infections, with an IND submission planned for 2026.
PureTech Health (NASDAQ: PRTC) has announced the launch of Celea Therapeutics, a new Founded Entity focused on developing treatments for serious respiratory diseases. The company's lead program, deupirfenidone (LYT-100), is Phase 3-ready and targets idiopathic pulmonary fibrosis (IPF), a rare and fatal lung disease.
Former Teva North America CEO Sven Dethlefs, PhD, has been appointed to lead Celea. Dr. Dethlefs brings over 25 years of pharmaceutical experience, including successful commercialization of AUSTEDO®, a deuterated medicine similar to deupirfenidone. The company recently completed a successful Phase 2b trial of deupirfenidone in December 2024, with FDA discussions expected by Q3 2025.
PureTech is seeking third-party funding to advance the program through Phase 3 and potential commercialization, aligned with its capital-efficient innovation model.
PureTech Health's (NASDAQ: PRTC) Founded Entity, Seaport Therapeutics, has initiated dosing in its Phase 2b BUOY-1 clinical trial for GlyphAllo™ (SPT-300), targeting Major Depressive Disorder (MDD). The study will evaluate approximately 360 patients over a six-week treatment period, with a primary focus on the Hamilton Depression Rating Scale-17.
GlyphAllo, a novel oral prodrug of allopregnanolone, demonstrated promising results in earlier trials, showing 9x greater allopregnanolone exposure compared to previous oral dosing methods. In Phase 2a, the drug significantly reduced stress hormone cortisol levels (p=0.0001) and was generally well-tolerated. The treatment targets the 280 million people globally affected by MDD, of whom 60% experience anxious distress.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) announced a significant leadership transition as CEO Bharatt Chowrira, PhD, JD, has stepped down from his position and Board membership after eight years with the company. The Board has appointed Robert Lyne as Interim CEO, effective immediately.
Lyne, who joined PureTech as Chief Portfolio Officer in January 2024, brings extensive experience in UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. The transition comes at a crucial time as the clinical-stage biotherapeutics company continues to advance its programs and focus on creating value for patients and shareholders.
PureTech's (Nasdaq: PRTC) Founded Entity Vor Bio (Nasdaq: VOR) has secured an exclusive global license agreement with RemeGen for telitacicept, a novel dual-target fusion protein, along with a $175 million private placement. The license agreement grants Vor Bio rights outside Greater China and includes an initial payment of $125 million ($45M upfront + $80M in warrants), with potential regulatory and commercial milestones exceeding $4 billion plus tiered royalties.
Telitacicept, already approved in China for multiple autoimmune conditions, is currently in global Phase 3 trials with results expected in H1 2027. Additionally, Vor Bio appointed Dr. Jean-Paul Kress as CEO and Chairman, replacing Dr. Robert Ang.
The private placement involves issuing warrants for 700 million shares at $0.25 per warrant, closing expected on June 27, 2025.PureTech Health (NASDAQ: PRTC) has published new research in BMC Pulmonary Medicine revealing critical insights into the experiences of people living with Idiopathic Pulmonary Fibrosis (IPF). The study, conducted with 106 IPF patients across the US, highlighted significant challenges in diagnosis, treatment, and quality of life.
Key findings include varied diagnosis timelines with frequent delays, low antifibrotic treatment uptake, and challenges in managing multiple health conditions. Nearly 90% of participants reported managing additional health challenges alongside IPF. The research also revealed that while supplemental oxygen therapy provides symptom relief, patients face logistical, financial, and emotional challenges.
The study, led by Dr. Camilla Graham and conducted in collaboration with experts from the University of Alabama, Vanderbilt University Medical Center, and the Pulmonary Fibrosis Foundation, emphasizes the need for enhanced disease awareness, streamlined diagnosis, and patient-centered treatment approaches.
Summary not available.